Table 3 Effectiveness of iron supplementation
Author | Year | Journal | Transfusion indication | Transfusion rate_iron (N, %) | Transfusion rate_control (N, %) | Hb_iron (g/dL) | Hb_control (g/dL) |
|---|---|---|---|---|---|---|---|
Park et al. [26] | 2019 | J Clin Med | Hb < 8 g/dL throughout the perioperative period Hemodynamic instability | 2 (6.9%) | 4 (12.8%) | Pre-OP (12.5 ± 1.3) POD 1D (10.3 ± 1.4) POD 5D (9.5 ± 1.2) POD 30D (12.8 ± 1.3) | Pre-OP (13.4 ± 1.1) POD 1D (10.7 ± 1.3) POD 5D (9.9 ± 1.6) POD 30D (12.6 ± 1.1) |
Heschl et al. [30] | 2018 | Eur J Anaesthesiol | Hb < 7 g/dL for healthy patients Hb < 8 g/dL for cardiopulmonary restriction patients | 40 (12)% | 79 (24%) | Pre-OP (12.9 ± 1.7) POD discharge (10.7 ± 1.3) | Pre-OP (12.2 ± 1.1) POD discharge (10.6 ± 1.1) |
Muñoz et al. [31] | 2014 | Blood transfusion | Hb < 8 g/dL throughout the perioperative periodHemodynamic instability | `21 (11.5%) | 48 (26.4%) | Pre-OP (13.8 ± 1.2) POD 3D (10.4 ± 1.6) POD 7D (10.6 ± 1.3) | Pre-OP (13.6 ± 1.2) POD 3D (9.2 ± 1.5) POD 7D (9.2 ± 2.2) |
Muñoz et al. [32] | 2012 | Br J Anaesth | Hb < 8 g/dL for healthy patients Hb < 9 g/dL for active cardiac disease | Low-dose: 20 (62%) High -dose: 29 (46%) | 16 (84%) | Low-dose Pre-OP (11.8 ± 1.2) POD 1D (8.7 ± 0.8) POD 7D (9.6 ± 0.7) High-dose Pre-OP (12.4 ± 1.3) POD 1D (9.1 ± 0.6) POD 7D (9.8 ± 0.9) | Pre-OP (12.5 ± 1.5) POD 1D (8.7 ± 1.0) POD 7D (10.1 ± 0.7) |
Na et al. [25] | 2011 | Transfusion | Hb: 6 ~ 7: 1 pack 5 ~ 6: 2 pack | 11 (20.4%) | 29 (53.7%) | Pre-OP (12.1 ± 1.3) Significantly higher Hb level than control group at POD 1D, 2D, 3D, 2 W, 6 W | Pre-OP (12.1 ± 1.2) Significantly lower Hb level than iron supplementation group at POD 1D, 2D, 3D, 2 W, 6 W |
Gonzalez-Porras et al. [29] | 2009 | Transfus Med | Hb < 7 g/dL for healthy patients Hb < 8 g/dL for poor tolerance of anemia Hb < 9 g/dL for cardiac or respiratory failure | Oral: 29 (20%) IV: 10 (20.4%) | 96 (31.5%) | Oral Pre-OP (14.3 ± 0.8) POD discharge (10.7 ± 0.1) IV Pre-OP (13.3 ± 0.2) POD discharge (10.3 ± 0.8) | Pre-OP (13.8 ± 1.4) POD discharge (10.7 ± 0.8) |
Mundy et al. [24] | 2005 | JBJS |  | 9 (18%) | 5 (10.2) | Men Pre-OP (15.1 ± 1.2) POD 1D (11.0 ± 1.8) POD 5D (10.8 ± 1.6) POD 3 weeks (13.0 ± 1.2) POD 6 weeks (13.8 ± 1.1) Women Pre-OP (13.3 ± 0.9) POD 1D (9.4 ± 1.3) POD 5D (10.3 ± 1.6) POD 3 weeks (11.9 ± 1.1) POD 6 weeks (12.5 ± 0.9) | Men Pre-OP (14.9 ± 0.9) POD 1D (11.4 ± 1.2) POD 5D (10.6 ± 0.9) POD 3 weeks (12.8 ± 0.8) POD 6 weeks (13.3 ± 1.4) Women Pre-OP (13.4 ± 1.3) POD 1D (9.5 ± 1.4) POD 5D (9.8 ± 1.1) POD 3 weeks (11.7 ± 1.4) POD 6 weeks (12.0 ± 1.4) |
Sutton et al. [27] | 2004 | JBJS | Â | Â | Â | Pre-OP (12.7) Post-OP (10.4) At review (12.4) | Pre-OP (12.9) Post-OP (10.5) At review (12.1) |
Weatherall et al. [28] | 2004 | ANZ J Surg |  |  |  | Pre-OP (14.0 ± 1.3) POD 10 weeks (13.3 ± 1.3) | Pre-OP (13.7 ± 1.1) POD 10 weeks (12.8 ± 1.1) |